MADD

MADD
Name	MADD
Synonyms	Multiple acyl-CoA dehydrogenase deficiency
Field	Medical genetics, Metabolism
Onset	Neonatal, infantile, juvenile, adult
Causes	Mutations in ETFA, ETFB, ETFDH
Diagnosis	Genetic testing, biochemical assays, tandem mass spectrometry
Treatment	Riboflavin, dietary management, supportive care

MADD

Introduction

MADD is a hereditary metabolic disorder of fatty acid, amino acid, and choline oxidation caused by defects in electron transfer flavoprotein components. First described in the context of neonatal metabolic crises and lipid storage myopathy, the condition links to clinical entities observed by clinicians working with Newborn screening programs, metabolic clinics, and researchers from institutions such as National Institutes of Health and University of Cambridge. Patients present across a spectrum from severe neonatal forms reported in case series to milder adult-onset phenotypes documented in literature from centers like Mayo Clinic and Charité – Universitätsmedizin Berlin.

History

Descriptions consistent with MADD emerged during expansions of organic acidurias research in the late 20th century, paralleling advances at laboratories including Massachusetts General Hospital, Great Ormond Street Hospital, and Vanderbilt University Medical Center. Molecular characterization followed cloning and sequencing work in molecular genetics groups at Harvard Medical School and University of Texas Southwestern Medical Center, culminating in identification of pathogenic variants in genes encoding electron transfer flavoprotein subunits by teams collaborating with Wellcome Trust–funded projects. The integration of tandem mass spectrometry into Newborn screening across regions such as California and Ontario increased detection and phenotype delineation.

Causes and Pathophysiology

MADD results from biallelic mutations in nuclear genes encoding components of the mitochondrial electron transfer flavoprotein complex, notably ETFA, ETFB, and ETFDH. Loss of function impairs transfer of electrons from multiple acyl-CoA dehydrogenases to the respiratory chain involving complexes characterized in studies of mitochondrial complex I and ubiquinone biology. Biochemically, defective electron transfer leads to accumulation of acylcarnitines and organic acids detected in analyses performed at centers like Nationwide Children’s Hospital and University of California, San Diego. Secondary effects include impaired oxidative phosphorylation described in research from Max Planck Institute for Biophysical Chemistry and altered redox states noted by investigators at Stanford University School of Medicine.

Symptoms and Diagnosis

Clinical presentations span severe neonatal metabolic acidosis, hypoglycemia, and congenital anomalies to later-onset muscle weakness, exercise intolerance, and episodic metabolic decompensation encountered in clinics such as Johns Hopkins Hospital and Seattle Children’s Hospital. Laboratory hallmarks identified via tandem mass spectrometry and organic acid analysis at reference laboratories include elevations of multiple acylcarnitines and dicarboxylic acids, patterns also reported in case series from The Hospital for Sick Children (Toronto) and Royal Hospital for Children, Glasgow. Diagnostic confirmation relies on genetic testing platforms employed by entities like GeneDx, Invitae, and academic sequencing centers at Broad Institute to detect pathogenic variants in the implicated genes. Muscle biopsy findings described by neuropathology groups at University College London may show lipid storage myopathy, while enzymology studies performed at biochemical genetics laboratories can demonstrate reduced electron transfer flavoprotein activity.

Treatment and Management

Management strategies emphasize metabolic stabilization during crises, nutritional interventions, and targeted pharmacotherapy. Riboflavin (vitamin B2) responsiveness documented in cohorts from Karolinska Institutet and University of Oxford leads to clinical improvement in many patients with pathogenic ETFDH variants; high-dose riboflavin protocols are used in outpatient programs at tertiary centers such as Cleveland Clinic. Dietary fat restriction, supplementation with medium-chain triglycerides overseen by dietitians at institutions like Boston Children’s Hospital, and avoidance of fasting are standard recommendations also applied in care plans at Hospital for Sick Children (Toronto). Supportive measures include management of cardiomyopathy or hepatic dysfunction by specialists at Mount Sinai Hospital and the use of physical therapy guided by teams at UCLA Medical Center.

Epidemiology and Risk Factors

MADD is a rare disorder with variable incidence estimates influenced by newborn screening programs across regions including Japan, Netherlands, and United States. Population-specific founder variants have been reported in cohorts from Quebec, Taiwan, and Finland, reflecting contributions from population genetics studies at universities such as McGill University and National Taiwan University Hospital. Risk relates to inheritance patterns observed in pedigrees studied by clinical geneticists at Columbia University Irving Medical Center; consanguinity increases the likelihood of homozygous pathogenic variants as described in reports from referral centers in Saudi Arabia and Turkey.

Impact and Advocacy

Patients and families affected by MADD engage with advocacy organizations and research networks to improve diagnosis, care, and research funding. Groups such as patient foundations associated with metabolic disorders collaborate with research consortia at European Reference Network for Rare Hereditary Metabolic Disorders (MetabERN), Global Genes, and academic partners at Yale School of Medicine to promote newborn screening expansion, genotype–phenotype registries, and clinical trials. Multidisciplinary teams encompassing specialists from American College of Medical Genetics and Genomics guidelines panels and clinicians at major pediatric centers work with families to develop long-term care plans, psychosocial support, and transition services to adult metabolic clinics like those at Kings College Hospital.

Category:Inborn errors of metabolism